Kornimate/medical-research-clean huggingface dataset:
effect of manual pressure and shotblocker on pain and injection satisfaction in intramuscular injection application

Conditions: Intramuscular Injection

Summary: this study was planned as a single blind randomized controlled experimental study to investigate the effect of manual pressure applied before injection and shotblocker's pain and injection satisfaction due to intramuscular injection. the sample of the study consisted of a total of 120 patients over the age of 18 who applied to the emergency service of a public hospital and were requested diclofenac sodium 75mg / 3ml. the patients were included in the experiment i (shotblocker), experiment ii (manual compression) and the control group with the randomization list created on the computer. in the shotblocker group, the shotblocker was kept throughout the injection, and in the manual compression group, manual pressure was applied to the injection area for 10 seconds before injection, and in the control group, im injection was applied without using any tools. before the injection, the heart rate and blood pressure values of the patient were measured and recorded. visual comparison scale and injection satisfaction scale were administered to the patient in the first minute after the injection. pulse and blood pressure values were measured and recorded again. finally, the patient introduction form was filled. parametric or nonparametric statistical tests and correlation test were used in the analysis of the data.


Eligibility criteria:
inclusion criteria: * he has not had an im injection in the last week, * upper respiratory tract infection patients in the examination department, where green field patients of the emergency service are located, * over the age of 18, * no complications related to im injections such as pain at the im injection site, abscess, infection, tissue necrosis, hematoma, * does not have pain anywhere in the body that will affect the work result, * are conscious and have no communication problem, * no vision or hearing problems, * not taking analgesic in the last 24 hours, * does not have any known chronic disease, * no psychiatric disorder, * diclofenac sodium ampoule has been ordered, * can evaluate "visual comparison scale and injection satisfaction scale" correctly, * individuals who volunteered to participate in the study and signed the written informed consent form were included. exclusion criteria: * not wanting to participate in the study, * patients who did not meet the study acceptance criteria were not included.

Keywords: shotblocker manual pressure i̇ntramuscular injection pain injection satisfaction
genesearch breast lymph node (bln) assay timing study

Conditions: Breast Cancer

Summary: this study is designed to collect data about the amount of time required to use the assay in clinical-use conditions.

assay turn-around-time will be collected at sites that are using the genesearch bln assay for intraoperative testing of sentinel lymph nodes. the sites must be planning to use the assay result to guide the decision to complete an axillary lymph node dissection.

Eligibility criteria:
inclusion criteria: * pre-operatively established diagnosis of invasive carcinoma of the breast * scheduled for axillary sentinel lymph node dissection as per standard of care at the clinical site for newly diagnosed breast cancer patients * patients for whom the genesearch™ bln assay will be used intra-operatively to make a decision for an axillary lymph node dissection * 18 years of age or older * female or male exclusion criteria: * previous diagnosis of lymphoma * subjects participating in other research studies that would interfere with their full participation in this study * patients and/or conditions with 'interfering substances' as listed in the ifu * patients who have had any pre-operative treatment for breast cancer including neoadjuvant and/or hormonal intervention such as aromatase inhibitors or tamoxifen

Keywords: sentinel lymph node metastasis
impact of spinal curves on asymmetric posture in idiopathic scoliosis

Conditions: Adolescent Idiopathic Scoliosis (AIS); Juvenile Idiopathic Scoliosis

Summary: asymmetric postures are often observed in patients with adolescent idiopathic scoliosis (ais) and are partially associated with instability in sitting and standing positions, as well as with imbalances in gait kinematic parameters in cases of moderate or severe scoliosis. based on the currently available data, no correlation has been identified between habitual postures in daily life and the presence of scoliosis. however, the asymmetry of preferred postures in relation to the morphological characteristics of the curves, and how this might contribute to the progression of the clinical condition due to prolonged uneven load distribution, has not yet been analyzed. understanding any preferential direction in postures habitually adopted by patients with idiopathic scoliosis could provide valuable insights for the conservative management of the condition. the aim of this study is to analyze the influence of the morphological characteristics of scoliotic curves (type and laterality) in patients with juvenile and adolescent idiopathic scoliosis on the choice of preferentially maintained asymmetric postures in daily life, using a descriptive questionnaire completed by family members and caregivers, compared to a group of non-scoliotic subjects. evaluate the effect of curve magnitude, age, sex, and risser grade on the choice of usual asymmetric postures. estimate the impact of prolonged maintenance of habitual asymmetric postures on the clinical progression in patients with juvenile and adolescent idiopathic scoliosis


Eligibility criteria:
scoliosis group: inclusion criteria: * diagnosis of juvenile or adolescent idiopathic scoliosis; * age between 6 and 18 years; * full spine x-ray in a standing position with anteroposterior projection performed within the year prior to completing the questionnaire. exclusion criteria: * diagnosis of secondary scoliosis * patients with neuromotor control disorders control group: inclusion criteria: * age between 6 and 18 years; * no diagnosis of sciolisis * full spine x-ray in a standing position with anteroposterior projection performed within the year prior to completing the questionnaire. exclusion criteria: - patients with neuromotor control disorders
trimodal prehabilitation in pancreatic cancer patients urdergoing neoadjuvant treatment

Conditions: Pancreatic Neoplasms

Summary: pancreatic cancer is a disease with a very poor prognosis and less than 10% of these patients live beyond 5 years from diagnosis. further, it is expected to become the second leading cause of death in the coming years. today, surgery remains the cornerstone in curing this disease, but the addition of chemotherapy is needed to improve survival. the impact of adjuvant treatment has been previously demonstrated and its efficacy is absolute. however, neoadjuvant chemotherapy (pre-surgery) improves the results after surgery (achieving earlier stages and with better prognosis) and would lead to better survival results. besides, the moment of cancer diagnosis is a moment of special receptivity to change lifestyles ("teachable moment"). multimodal prehabilitation includes 1) physical exercise; 2) nutritional and 3) psychological support. the potential advantages of prehabilitation during neoadjuvant therapy would be 1) the possibility of achieving a better physical condition to face surgery; 2) fewer postoperative complications; 3) more likely to receive adjuvant treatment after surgery; 4) better physical function at the end of treatments. to date, most studies have focused on lung and prostate cancer, with a high prevalence of men in the series. this strategy has previously been explored, showing that it is safe and feasible, (loughney et al). we have not identified any study of trimodal prehabilitation during neoadjuvant treatment and none that has integrated motivational strategies to maintain adherence. patients during chemotherapy have perceived several adverse effects that could limit adherence to the program. in this regard, a review on the motivation and exercise in cancer survivors shows that it is necessary to apply theoretical frameworks to understand cognitive and motivational processes and develop educational interventions. the self-determination theory is one of the motivational theories most applied today to the analysis of factors related to the adoption of healthy lifestyles. likewise, patients who are motivated are more likely to improve healthy habits and obtain greater adherence to exercise performance. therefore, we aimed of carrying out an intervention (pilot study) in ten patients to describe the feasibility of a trimodal prehabilitation program in the hospital environment, applying motivational strategies and a mixed-method (face-to-face and online).

outcome measures refer to feasibility of the intervention: recruitment attendance to the training sessions attendance to psychologist and nutritionist sessions and also to physical condition cardiorespiratory fitness muscular strength body composition physical activity quality of life fatigue score

Eligibility criteria:
inclusion criteria: * more than 18 years old * ecog 0-2 * being able to complete the mile-time test * stages i-iii * being able to understand the informed consent * pancreatic cancer diagnosed exclusion criteria: * metastasic cancer

Keywords: exercise pancreatic cancer trimodal
cyproterone acetate in treating hot flashes following surgical or chemical castration for prostate cancer

Conditions: Hot Flashes; Prostate Cancer

Summary: rationale: cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. it is not yet known which regimen of cyproterone acetate is more effective for hot flashes. purpose: randomized phase iii trial to determine the effectiveness of cyproterone acetate in treating patients who have hot flashes following surgical or chemical castration for prostate cancer.

objectives: * determine the efficacy of cyproterone acetate in patients with hot flashes following bilateral orchiectomy or medical castration for prostate cancer. * compare the effectiveness of two doses of cyproterone acetate in these patients. * determine the safety of this regimen in these patients. * determine the impact of this regimen on the quality of life of these patients. outline: this is a randomized, double-blind, placebo controlled study. patients receive one of two doses of oral cyproterone acetate or placebo for 12 weeks, followed by a 6-9 month open label extension period with all patients receiving cyproterone acetate. quality of life is assessed. projected accrual: not specified

Eligibility criteria:
disease characteristics: * prostate cancer patients who have undergone bilateral orchiectomy or medical castration (lhrh agonist drugs) and are experiencing hot flashes * hot flashes are defined as: * at least 3 to 4 moderate to severe hot flashes per day or 21 per week at baseline * present at least 1 month prior to study patient characteristics: age: * 18 and over performance status: * ecog 0-1 life expectancy: * greater than 12 months hematopoietic: * wbc at least 3,000/ul * platelet count at least 75,000/ul * hemoglobin at least 6.2 mmol/l hepatic: * bilirubin no greater than 1.8 mg/dl * sgpt no greater than 96 u/l * sgot no greater than 90 u/l * ldh no greater than 600 renal: * bun no greater than 42 mg/dl * creatinine no greater than 3.39 mg/dl cardiovascular: * no cardiovascular risks (e.g., history of angina pectoris) unless controlled by medical or surgical therapy * no known history of thromboembolic disease other: * comprehend and understand english language * no other prior malignancy within the past 5 years except treated squamous or basal cell skin cancer or superficial bladder carcinoma prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least a 4 week washout period is required if prior antineoplastic or cytotoxic chemotherapy has been used endocrine therapy: * at least a 4 week washout period is required if prior estrogens, antiandrogens (e.g., flutamide or bicalutamide), progestational agents, or corticosteroids have been used * no concurrent herbal medications with known hormonal ingredients (i.e., phytoestrogens) radiotherapy: * not specified surgery: * see disease characteristics other: * at least a 4 week washout period is required if prior clonidine or monoamine oxidase inhibitors have been used

Keywords: stage iv prostate cancer recurrent prostate cancer hot flashes
is protein s100b a predictor of first-to-chronic seizure conversion in adults?

Conditions: Epilepsy; Seizures, Epileptic

Summary: seizures represent an important clinical problem, accounting for at least 40% of adult onset epilepsy. predicting seizure recurrence in subjects experiencing a first seizure is difficult due to the lack of prognostic biomarkers. recent evidence has indicated that blood-brain barrier (bbb) dysfunction constitutes an etiological factor to seizures. in particular, it has been shown that modification of bbb permeability is associated with seizure activity. in addition, it was demonstrated that bbb permeability can be assessed by measuring serum level of the protein s100b. based on these data and considerations the investigators will test whether the extent of bbb damage at time of first seizure is predictive for seizure recurrence. the main objective of this study is to evaluate the association between the absolute (ng/ml) serum s100b levels (measured at time of the first seizure) and the experience, or not, of seizure recurrence within one year of follow-up.

the secondary objectives of this study are to investigate the: a) prognostic capacity of serum s100b levels to predict seizure recurrence. b) association between the variation (%) of serum s100b levels between first seizure episode and scheduled follow-up (d14-d28) and seizure recurrence. c) correlation of s100b with il-1b, il-6, nse serum levels at the same time points. d) association of serology data with: a) eeg profile (normal/abnormal); b) recurrence of seizures (y/n). e) comparison of s100b serum levels in lesional vs non-lesional patients. f) establishment of a bio-bank (serum and cells).

Eligibility criteria:
inclusion criteria: * the patient has been correctly informed. * the patient must have given his informed and signed consent. * the patient must be insured or beneficiary of a health insurance plan. * the patient is at least (≥) 18 years old and less than (\<) 60 years old. * the patient has experienced a first generalized, epileptic seizure (patients with partial onset and secondary generalization can also be included). * the seizure has occurred less than 24 hours ago. exclusion criteria: * the patient is participating in another study that may interfere with the results or conclusions of this study. * within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study. * the patient is in an exclusion period determined by a previous study. * the patient is under judicial protection. * the patient refuses to sign the consent. * it is impossible to correctly inform the patient. * the patient is pregnant or breast-feeding (mri contraindicated). * patient has a previous abnormal brain imaging (mri). * patient has abnormal biological tests for toxicology (alcohol, cocaine and cannabis tests), blood ionogram (hyponatremia \ 5n), inflammatory syndrome (elevated c-reactive protein).
debakey cardiovascular magnetic resonance study

Conditions: Cardiovascular Diseases

Summary: while advancements in cardiac magnetic resonance (cmr) have improved image quality, it is unclear how these improvements are connected to the clinical evaluation of individuals with cardiovascular disease. the aim of this large prospective registry revolves around 4 key principles: 1) utilize cmr to gain additional pathophysiologic insights into cardiovascular disease, 2) understand how cmr compares to alternative cardiovascular diagnostic modalities, 3) determine how cmr affects clinical management decisions, and 4) establish a link between cmr findings and long term prognosis in patients with known or suspected cardiovascular disease. the ultimate aim is to utilize cmr to improve patient outcomes. cmr techniques to be studies include function, fibrosis, and flow. focus areas include valvular heart disease, ischemic heart disease, cardiomyopathies, and vascular disease.

patient population, recruitment, and consent: patients presenting to the houston methodist debakey cmr laboratory will be enrolled from april 2008 to april 2038. it is expected that up to 100,000 patients may be enrolled during this period. subjects will be identified based on their referral to the houston methodist debakey cmr laboratory for mri studies during the proposed study period. after enrollment, a registered nurse or physician will perform a thorough structured patient interview and/or review of electronic health records to document baseline medical history including cardiac risk factors, symptoms, medication usage, and prior procedure history. a small blood sample will be drawn and stored for future biomarker and/or genetic testing analysis. annual follow up for clinical status will be performed via review of electronic health records; structured telephone interviews with the patients, relatives, and/or their health care providers; and/or the social security death index database.

Eligibility criteria:
inclusion criteria: * all patients presenting to the houston methodist cmr laboratory with known or suspected cardiovascular disease. exclusion criteria: * unable to provide informed consent

Keywords: cardiovascular disease cardiac magnetic resonance myocardial fibrosis valvular heart disease ischemic heart disease cardiomyopathy
a study of ritonavir/indinavir combination in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to determine how many hiv-infected patients continue taking ritonavir/indinavir combination after having taken indinavir three times a day as part of their anti-hiv drug therapy. this study also examines the safety and effectiveness of the ritonavir/indinavir combination.


Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * cd4 cell count greater than 100 cells/microliter. * hiv rna levels greater than 400 copies/microliter using the roche ultrasensitive assay. * no acute illness. * consent of parent or guardian if less than legal age. * no prior enrollment in this study. * all entry criteria for this study met within 15 days prior to enrollment. exclusion criteria co-existing condition: patients with any of the following symptoms or conditions are excluded: any condition that in the opinion of the investigator may obscure proper observation of the safety or activity of the treatment regimens used in this study. concurrent medication: excluded: * concurrent non-nucleoside reverse transcriptase inhibitors as part of the antiretroviral regimen. * any of the following medications with ritonavir: * midazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil, terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine, propoxyphene, piroxicam, pimozide, dihydroergotamine, and ergotamine. * any of the following medications with indinavir: * terfenadine, astemizole, cisapride, triazolam, midazolam. no requirement for rifampin or ketoconazole. * any concurrent treatment with other protease inhibitors. * other concurrent medication (including over-the-counter medicine or alcohol) without the knowledge and permission of the primary investigator. patients with the following prior conditions are excluded: * history of significant drug hypersensitivity. * psychiatric illness that precludes compliance with the protocol. * receipt of investigational drug within 30 days prior to administration of study drug. * history of acute or chronic pancreatitis. * anticipation of poor patient compliance with protocol. prior medication: excluded: prior treatment with ritonavir. risk behavior: excluded: history of active substance abuse (i.e., recreational drugs or alcohol). included: - indinavir 800 mg three times a day plus unspecified nucleosides for at least 3 months.

Keywords: drug therapy, combination adolescent behavior hiv protease inhibitors ritonavir indinavir
sexual needs of adolescents living with hiv since childhood

Conditions: Hiv; Perinatal HIV Infection

Summary: to improve the knowdelge about the sexual health needs of perinatally hiv-infected adolescents living in france.

20 individual semi-structured interviews will be conducted with 20 young adults living with hiv sinc childhood and living in france. the aim of this study is to identify their sexual needs through exploring their personal experience of sexuality during their adolescence. the investigator intend to explore communication about the disease and sexuality within their families ; communication about sexual health with health care professionnals ; whether sexuality has arrose difficulties related to their chronic condition such as rejection or sadness ; whether there are differences in sexual needs regarding gender. a thematic analysis will be conducted by three researchers.

Eligibility criteria:
inclusion criteria: * age between 18 and 25 yo * hiv-1 or hiv-2 diagnosis before the age of 13 * non opposition to participate to the study * be affiliated to a social security scheme (except aide médicale de l'etat (ame)) exclusion criteria: * having contracted hiv infection through sexual contact * persons under guardianship or custodianship, or deprived of their liberty by a judicial or administrative decision * associated illnesses or disabilities that makes participation impossible

Keywords: hiv sexual health adolescent sexual needs
different ultrafiltration rates and intradialytic hypotension.

Conditions: Hemodialysis; Intradialytic Hypotension

Summary: finding relationship between different ultrafiltration rates and intradialytic hypotension in attempt to find the optimal cut off points.

this observational study will be carried upon hemodialysis patients with different ultrafiltration rates at each session to study the association between ultrafiltration rates and intradialytic hypotension. thus identifying the optimal cut off of ultrafiltration rate points for each patient

Eligibility criteria:
inclusion criteria: all patients aged 18 year or older on maintenance haemodialysis for at least 3 consecutive months receiving 3 sessions weekly. - exclusion criteria: patients aged \< 18 years old. patients on recent haemodialysis \< 3 months. pregnant women. patients with malignancy, severe infections or sepsis. patients with major bleeding. patients who cannot go upper limb monitoring of blood pressure. patients with severe heart failure (nyha) class 3 or more. patients with severe anemia, hemoglobin less than 6 g/dl.

Keywords: ultrafiltration rates intradialytic hypotension